Key Takeaways
- • Palliser Capital is opposing the revised €53-per-share offer for Recordati from Respighi BidCo, the vehicle backed by CVC and Groupe Bruxelles Lambert, and will not tender its shares, according to Palliser's Business Wire statement and Il Sole 24 Ore.
- • Palliser calls the bid "best and final" and argues the €53 price undervalues Recordati's pipeline and cash-generation profile.
- • The tender period has been extended to October 23, 2026, and Palliser has asked the board to clarify by October 16 whether independent directors unanimously recommend the offer.
- • Deal coverage indicates more than half of Recordati's shares are already tendered or otherwise controlled on the CVC side, limiting the practical impact of opposition.
- • Opposition may shape terms, disclosure, or squeeze-out dynamics more than it blocks completion, with board communications and tender updates the key signals to watch.
Summary
Palliser Capital has publicly opposed the revised €53-per-share offer for Recordati, the Italian specialty pharmaceutical company, from Respighi BidCo, a vehicle backed by CVC and Groupe Bruxelles Lambert (GBL). According to Palliser's Business Wire statement and Italian press coverage including Il Sole 24 Ore, the firm will not tender its shares and argues that the price undervalues the company. Palliser has characterized the bid as best and final.
The tender period has been extended to October 23, 2026. Palliser has asked Recordati's board to clarify by October 16 whether the independent directors unanimously recommend the offer, seeking a clearer public record of the board's position as the revised bid proceeds.
Deal coverage indicates that more than half of Recordati's shares have already been tendered or are otherwise controlled on the CVC side, which raises the practical bar for opposition. Best-and-final labeling is typically intended to close an auction, though activist shareholders often test whether such language leaves room for negotiation or minority protections.
For event-driven investors, the situation resembles a classic European take-private: a specialty pharma asset, a sponsor-led bid with a large strategic co-investor, and a minority holder contending that the public price does not capture the company's pipeline and cash-generation profile. The October 16 clarification deadline and October 23 tender end date are the near-term catalysts.
The central question for allocators is whether Palliser's valuation critique can change the outcome. If majority support already rests with the buyer group, opposition may influence terms, disclosure, or squeeze-out dynamics more than it blocks completion. Upcoming board communications and tender updates should indicate which path is more likely.
The tender period has been extended to October 23, 2026. Palliser has asked Recordati's board to clarify by October 16 whether the independent directors unanimously recommend the offer, seeking a clearer public record of the board's position as the revised bid proceeds.
Deal coverage indicates that more than half of Recordati's shares have already been tendered or are otherwise controlled on the CVC side, which raises the practical bar for opposition. Best-and-final labeling is typically intended to close an auction, though activist shareholders often test whether such language leaves room for negotiation or minority protections.
For event-driven investors, the situation resembles a classic European take-private: a specialty pharma asset, a sponsor-led bid with a large strategic co-investor, and a minority holder contending that the public price does not capture the company's pipeline and cash-generation profile. The October 16 clarification deadline and October 23 tender end date are the near-term catalysts.
The central question for allocators is whether Palliser's valuation critique can change the outcome. If majority support already rests with the buyer group, opposition may influence terms, disclosure, or squeeze-out dynamics more than it blocks completion. Upcoming board communications and tender updates should indicate which path is more likely.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.